Year: 2024

– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models – – Proof-of-concept study of ziftomenib plus imatinib in patients with advanced GIST after imatinib failure to begin in 1H 2025 – SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported preclinical data supporting the development of the Company’s menin inhibitor, ziftomenib, for the treatment of advanced gastrointestinal stromal tumors (GIST). The new findings are being presented at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. A copy of the poster, entitled “Menin...

VANCOUVER, British Columbia, Oct. 24, 2024 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (“Orezone”) is pleased to provide an update on the hard rock expansion at its Bomboré Gold Mine. The hard rock expansion is forecasted to increase annual gold production to over 170,000 ounces, an approximate 50% increase from current levels, with first gold planned in Q4-2025. Site works are well-advanced with the plant-site area cleared and all major earthworks complete. Laydown areas have been prepared and are ready to receive construction equipment, offices, and major plant deliveries. Camp upgrades for construction supervision and teams are also now operational. Engineering and Procurement Lycopodium Minerals Canada (“Lycopodium”) was awarded the engineering and procurement contract and is ahead of schedule on both...

PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) — Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies. Jonathan Guarino, CPA, CGMA, Senior Vice President and Chief Financial Officer of Soligenix, will be presenting at 9:00 AM ET on October 30th. Members of Soligenix management will also be holding one-on-one investor meetings throughout the day. Interested investors...

Figure 1MD-RTEC Option for LithiumFigure 2JB (North) Lithium OccurrencesFigure 3Galinée ProjectFigure 4Galinée 2024 Drilling ProgramFigure 5Galinée 2024 Drilling ProgramFigure 6Galinée 2024 Drilling ProgramFigure 7Wookie ProjectFigure 8Shire ProjectFigure 9Iceberg Spodumene ShowingFigure 10White Stripes and Surge ShowingsFigure 11White Lightning and Snow Fox ShowingsMONTREAL, Oct. 24, 2024 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland”) (TSX-V: MD), in partnership with Rio Tinto Exploration Canada Inc. (“RTEC”), is pleased to announce preliminary results from the first drilling campaign for lithium on the Galinée project, and results from surface prospecting on Galinée, Wookie, and Shire projects. The 2024 drilling...

– Continued, progressive improvement in motor function and achievement of motor milestones at 12-months post-treatment represents an important and statistically significant change, in contrast to the disease course observed in BridgeBio’s ongoing CANinform natural history comparator study – Significant and sustained reductions in N-acetylaspartate (NAA) levels in urine, cerebrospinal fluid (CSF), and brain in all participants who received low dose; encouraging trends of further reduction in urine NAA in participants who received high dose BBP-812 – If approved, BridgeBio’s gene therapy for Canavan disease could be the first therapeutic option for children born with this fatal neurodevelopmental disorder PALO ALTO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio ), a commercial-stage...

TORONTO, Oct. 24, 2024 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drone solutions and enterprise SaaS (Software-as-a-Service) solutions, today announces that its subsidiary, ZenaDrone, is acquiring a United States Design Patent for a drone design pertaining to the second-generation drone design used in its ZenaDrone 1000 product. This patent includes changes to the first-generation design to improve flight times and increase the payload capacity. The patent (US D1,005,883 S) was granted by the US Patent and Trademark Office in November 2023 by ZenaTech’s former parent company. The patent acquisition is subject to shareholder and regulatory approvals that may be required. Contained in the patent are designs for rotating arms enabling...

NEW YORK and MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today announced the appointment of Lou Barbato, M.D., as Chief Medical Officer (CMO) effective immediately. Dr. Barbato’s drug development experience includes senior clinical development and operational roles at Jazz Pharmaceuticals, AbbVie, Biogen, Novartis, and Solvay. He joins Incannex as the company continues to advance its lead clinical-stage programs in obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis. “We are delighted to welcome Dr. Barbato to Incannex as our Chief Medical Officer. With an established track record in directing drug...

ROUYN-NORANDA, Quebec, Oct. 24, 2024 (GLOBE NEWSWIRE) — Mines Abcourt Inc. (“Abcourt” or the “Company”) (TSX Venture : ABI) (OTCQB : ABMBF) is pleased to announce its most recent channel sampling results from the second phase of stripping conducted in September-October 2024. Phase 2 made it possible to link together stripping No. 2 and 3 of the first phase of work carried out in the summer of 2024 with the former Cambior stripping carried out at the end of the 80s. The most significant intersection is from channel 11, which is 10.4 g/t gold over 12 metres including 29 g/t gold over 4 metres. The channels, 15 in total (including Phases 1 and 2), are all 0.5 metre long and are connected to each other. Each of the channels averages 6 to 8 cm deep and intersects perpendicularly with the mineralized zones, which are oriented east-west...

CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD) annual conference, taking place October 29 – November 1, in Madrid, Spain. The presentations will include updates on new scientific findings from Biogen’s Alzheimer’s portfolio, highlighting data on different aspects of treatment and data examining preclinical Alzheimer’s disease and race. “These data showcase the breadth of our Alzheimer’s disease research and our ongoing commitment to scientific innovation,” said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. “We remain dedicated to advancing the field of research and treatment for this disease in order to better serve the millions of patients, families and providers in the Alzheimer’s...

– Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients with non-small cell lung cancer (NSCLC) – First safety data presented from combination study of PRT3789 and docetaxel demonstrated an acceptable safety profile – First preclinical proof-of-concept data presented from precision antibody drug conjugate program deploying a novel SMARCA2/4 dual degrader payload WILMINGTON, Del., Oct. 24, 2024 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the presentation of additional data from its ongoing Phase 1 open-label, dose-escalation trial of PRT3789, a first-in-class, highly selective SMARCA2 degrader designed to treat cancer patients with a SMARCA4 mutation. The data were...